STAAR Surgical Merger with Alcon Terminated After Shareholder Rejection
STAA sits 63% above its 52-week low of $13.5 on elevated volume (5.6× avg).
Summary
STAAR Surgical Company announced the termination of its merger agreement with Alcon Research, LLC, following a special meeting where shareholders voted against the merger proposal.
Key Events · M&A and Partnerships · STAA
-
Merger Agreement Terminated
The Agreement and Plan of Merger with Alcon Research, LLC, dated August 4, 2025, was terminated effective January 6, 2026.
-
Shareholders Reject Merger Proposal
At a special meeting, shareholders voted against the proposal to adopt the Merger Agreement, with 27,339,877 votes against compared to 14,904,915 votes for.
-
No Termination Fees
Neither STAAR Surgical nor Alcon will be required to pay any termination fees as a result of the agreement's termination.
Analysis · STAA · Industrial Applications And Services
The termination of the merger agreement with Alcon is a critical development for STAAR Surgical, as it removes the previously announced acquisition and any potential premium associated with it. The shareholder vote against the merger indicates a significant divergence between the company's proposed strategic direction and investor sentiment. This event will likely lead to a re-evaluation of STAAR Surgical's standalone strategy and could impact investor confidence.
At the time of this filing, STAA was trading at $22.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $13.50 to $30.81. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.